Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabazitaxel - Sanofi

Drug Profile

Cabazitaxel - Sanofi

Alternative Names: 116 258; Jevtana; RPR 116258; RPR-116258A; Taxoid XRP6258; Taxoid-116258; TXD 258; XRP-6258

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer AIO Studien gGmbH; Bristol Haematology and Oncology Centre; European Organisation for Research and Treatment of Cancer; German Breast Group; Sanofi; SCRI Development Innovations; Sidney Kimmel Cancer Center; University Hospitals Bristol NHS Foundation Trust
  • Class Amines; Antineoplastics; Benzene derivatives; Esters; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Brain metastases; Breast cancer; Germ cell cancer; Liposarcoma; Penile cancer; Small cell lung cancer
  • Phase I/II Solid tumours
  • No development reported Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Urogenital cancer

Most Recent Events

  • 13 Oct 2023 The Memorial Sloan-Kettering Cancer Center & Sanofi completes a phase II trial for Prostate cancer (Metastatic disease, Combination therapy) in USA (NCT02218606)
  • 01 Aug 2022 The district court dismisses infringement claim related to the 592 patent filed against generic filers by Sanofi in
  • 28 Jul 2022 Sanofi has four Orange Book listed patents protection for Cabazitaxel in US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top